Absorption, metabolism, and excretion of [ 14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

Drug Metabolism and Disposition

Volumn 37, Issue 3, 2009, Pages 536-544

  He, Handan ^a   Tran, Phi ^a   Yin, Hequn ^a   Smith, Harold ^a   Batard, Yannick ^a   Wang, Lai ^a   Einolf, Heidi ^a   Gu, Helen ^a   Mangold, James B ^a   Fischer, Volker ^b   Howard, Dan ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 4A11; DIPEPTIDYL PEPTIDASE IV; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; VILDAGLIPTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG FECES LEVEL; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; ISOTOPE LABELING; LIVER MICROSOME METABOLISM; LIVER SLICE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADAMANTANE; AREA UNDER CURVE; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYDROLYSIS; HYPOGLYCEMIC AGENTS; MASS SPECTROMETRY; NITRILES; PROTEIN BINDING; PYRROLIDINES;

EID: 61449170189     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.023010     Document Type: Article

References (19)

1. Ahrén B, Landin-Olsson M, Jansson P-A, Svensson M, Holmes D, and Schweizer A (2004) Inhibition of dipeptidyl pep tidas e-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 85:2078-2084.
2. Ahrén B, Simons son E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Båvenholm P, Efendic S, Eriksson JW, et al. (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes. Diabetes Care 25:869-875.
3. Balkan B, Kwasnik L, Miserendino R, Holst JJ, and Li X (1999) Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331.
4. Deacon CF, Johnsen AH, and Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957.
5. Drucker DJ (2003) Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 12:87-100.
6. Gutniak M, Orskov C, Hoist JJ, Ahrén B, and Efendic S (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322.
7. Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, and Ahrén B (1997) GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care 20:1874-1879.
8. He H, Tran P, Yin H, Smith H, Flood D, Kramp R, Filipeck R, Fischer V, and Howard D (2009) Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. Drug Metab Dispos 37:545-554.
9. He YL, Sabo R, Campestrini J, Wang Y, Riviere GJ, Nielsen JC, Rosenberg M, Ligueros-Saylan M, Howard D, and Dole WP (2008) The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol 65:338-346.
10. He YL, Sadler BM, Sabo R, Balez S, Wang Y, Campestrini J, Laurent A, Ligueros-Saylan M, and Howard D (2007a) The absolute bioavailability and population-based pharmacokinetic modeling of a novel dipeptidylppeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 46:787-802.
11. He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Hoist JJ, Schwartz HS, Nielsen JC, and Ligueros-Saylan M (2007b) Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 46:577-788.
12. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, et al. (2005) Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of DPP-4, in healthy subjects; results from two randomized double-blind, placebocontrolled studies with single oral dose. Clin Pharmacol Ther 78:675-688.
13. Kieffer TJ and Habener JF (1999) The glucagons-like peptides. Endocr Rev 20:876-913.
14. Mentlein R (1999) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9-24.
15. Mest HJ and Mentlein R (2005) Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 48:616-620.
16. Reimer MK, Holst JJ, and Ahrén B (2002) Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146:717-727.
17. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, and Cosio FG (2004) Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 12:929-937.
18. Sunkara G, Sabo R, Wang Y, He YL, Campestrini J, Rosenberg M, Howard D, and Dole WP (2007) Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers Br J Clin Pharmacol 47:1152-1158.
19. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, and Hughes TE (2003) 1-[[(3-Hydroxy-1-adamantyl)amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46:2774-2789.